Marie T Filbin

6399577, Jun 4, 2002

Jan 25, 2001

09/769701

Marie T. Filbin - New York NY

Research Foundation of CUNY, Hunter College - New York NY

A61K 3170

514 23, 514 2, 514 8, 514 25, 514557

This invention relates to the novel identification of myelin-associated glycoprotein (âMAGâ) as a potent inhibitor of neural regeneration. More particularly, this invention relates to compositions and methods useful for reversing inhibition of neural regeneration in the central and peripheral nervous system. Assays to monitor the effects of MAG on neural regeneration and to identify agents which will block or promote the inhibitory effects of MAG on neural outgrowth are provided. Screening methods for identifying such agents are also provided. This invention also relates to compositions and methods using agents that can reverse the inhibitory effects of MAG on neural regeneration. Methods for regulating and for promoting neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering at least one of the compositions according to this invention are provided.

7741310, Jun 22, 2010

May 4, 2001

10/275513

Marie T. Filbin - New York NY, US
Rajiv R. Ratan - Southborough MA, US

Research Foundation of the City University of New York - New York NY
Beth Israel Deaconess Medical Center - Boston MA

C12N 5/071
A01N 43/04

514 46, 435368

This invention relates to the novel identification of arginase as an enzymatic activity which can reverse inhibition of neuronal regeneration in the central and peripheral nervous system. Assays to monitor the effects of various agents on arginase expression and thus on neuronal regeneration and repair and to identify agents which will block or promote the inhibitory effects on neuronal outgrowth are provided. This invention also relates to compositions and methods using agents that can reverse the inhibitory effects of myelin on neural regeneration by affecting arginase activity or putrescine and derivative polyamine levels in a neuron. Methods for regulating and for promoting (or repressing) neuronal growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with conditions, disorders or diseases, comprising the step of administering at least one of the compositions according to this invention, are provided.

7842666, Nov 30, 2010

Dec 20, 2002

10/327213

Marie T. Filbin - New York NY, US
Marco Domeniconi - New York NY, US
Zixuan Cao - Elmhurst NY, US

Research Foundation of City University of New York - New York NY

A61K 38/17
A61K 38/08
A61K 38/04
C07K 7/06
C07K 14/47

514 12, 530350, 530324, 530328, 530329, 530330, 514 15, 514 17

The present invention relates generally to products, compositions and methods useful for promoting neural repair and regeneration. The products and compositions of this invention include myelin-associated glycoprotein (MAG) derivatives that are inhibitors of endogenous MAG (e. g. , mutant MAG proteins) and Nogo Receptor (NgR) binding inhibitors that are peptides derived from MAG, Nogo and OMgp that can bind to NgR and block NgR signaling. Peptides that can bind and activate NgR signaling are also provided. Inhibitory MAG derivatives and NgR binding inhibitors are useful for blocking the inhibition of neural regeneration mediated by proteins such as MAG, Nogo and/or OMgp in the nervous system. These inhibitors are also useful for treating neural degeneration associated with injuries, disorders or diseases.

8163700, Apr 24, 2012

Nov 12, 2010

12/945683

Marie T. Filbin - New York NY, US
Marco Domeniconi - New York NY, US
Zixuan Cao - Elmhurst NY, US

Research Foundation of City University of New York - New York NY

A61K 38/04
A61K 38/08
A61K 38/16

514 177, 514 213, 514 216, 514 218

The present invention relates generally to products, compositions and methods useful for promoting neural repair and regeneration. The products and compositions of this invention include myelin-associated glycoprotein (MAG) derivatives that are inhibitors of endogenous MAG (e. g. , mutant MAG proteins) and Nogo Receptor (NgR) binding inhibitors that are peptides derived from MAG, Nogo and OMgp that can bind to NgR and block NgR signaling. Peptides that can bind and activate NgR signaling are also provided. Inhibitory MAG derivatives and NgR binding inhibitors are useful for blocking the inhibition of neural regeneration mediated by proteins such as MAG, Nogo and/or OMgp in the nervous system. These inhibitors are also useful for treating neural degeneration associated with injuries, disorders or diseases.

8367615, Feb 5, 2013

Mar 30, 2007

12/225639

Marie T. Filbin - New York NY, US
Sari S. Hannila - New York NY, US

Research Foundation of City University of New York - New York NY

A61K 38/57

514 177, 514 203

The present invention provides methods for stimulating neuronal survival, growth and regeneration by administering SLPIs to animals, such as humans. These methods can be used to treat a variety of neurological conditions such as neural injuries and degenerative diseases in subjects in need thereof.

8598315, Dec 3, 2013

Oct 2, 2008

12/681243

Marie T. Filbin - New York NY, US
Sari S. Hannila - New York NY, US

Research Foundation of City University of New York - New York NY

A61K 38/04
A61K 38/10
C07K 7/08

530326

This invention relates to novel protein transduction domains (PTDs) derived from secretory leukocyte protease inhibitor (SLPI). SLPI-derived PTDs are able to deliver cargo moieties in vivo and in vitro into the cytoplasm and nucleus of a host cell. The invention also relates to a transduction complex comprising one or more SLPI-derived PTDs linked or fused to one or more cargo moieties, which may comprise, for example, proteins, nucleic acids, lipids, carbohydrates, small molecules and other chemical compounds. The invention also relates to the manufacture of SLPI-derived PTDs, complexes comprising them; compositions comprising SLPI-derived PTDs or complexes; and utilization of SLPI-derived PTDs or complexes comprising them for therapeutic, diagnostic and research methods involving delivery of heterologous molecules across cellular membranes, and especially, across nuclear membranes.

20030229134, Dec 11, 2003

Apr 14, 2003

10/414506

Marie Filbin - New York NY, US
Elena Nikulina - Astoria NY, US

A61K031/4015

514/424000

The invention relates to the novel identification of inhibitors of phosphodiesterase type 4 (“PDE4”) as agents which can reverse inhibition of neural regeneration in the mammalian central and peripheral nervous system. The invention provides compositions and methods using agents that can reverse the inhibitory effects on neural regeneration by regulating PDE4 expression. A composition comprising at least one PDE4 inhibitor in an amount effective to inhibit PDE4 activity in a neuron when administered to an animal is provided. Methods for regulating (e.g., promoting) neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering to an animal a composition comprising a therapeutically effective amount of an agent which inhibits phosphodiesterase IV activity in a neuron are provided.

20090253782, Oct 8, 2009

Jul 18, 2007

12/309500

Rajiv R. Ratan - Scarsdale NY, US
Marie T. Filbin - New York NY, US

A61K 31/352
A61P 25/28

514454

The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.